LENSAR (LNSR) Competitors $13.39 +0.30 (+2.29%) As of 11:05 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LNSR vs. AVNS, EMBC, BVS, KIDS, RXST, BFLY, AXGN, DCTH, SMLR, and TMCIShould you be buying LENSAR stock or one of its competitors? The main competitors of LENSAR include Avanos Medical (AVNS), Embecta (EMBC), Bioventus (BVS), OrthoPediatrics (KIDS), RxSight (RXST), Butterfly Network (BFLY), AxoGen (AXGN), Delcath Systems (DCTH), Semler Scientific (SMLR), and Treace Medical Concepts (TMCI). These companies are all part of the "medical equipment" industry. LENSAR vs. Its Competitors Avanos Medical Embecta Bioventus OrthoPediatrics RxSight Butterfly Network AxoGen Delcath Systems Semler Scientific Treace Medical Concepts Avanos Medical (NYSE:AVNS) and LENSAR (NASDAQ:LNSR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, media sentiment, analyst recommendations, earnings and valuation. Do analysts prefer AVNS or LNSR? LENSAR has a consensus price target of $15.00, indicating a potential upside of 12.02%. Given LENSAR's stronger consensus rating and higher probable upside, analysts plainly believe LENSAR is more favorable than Avanos Medical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avanos Medical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00LENSAR 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is AVNS or LNSR more profitable? Avanos Medical has a net margin of -55.80% compared to LENSAR's net margin of -99.17%. Avanos Medical's return on equity of 6.26% beat LENSAR's return on equity.Company Net Margins Return on Equity Return on Assets Avanos Medical-55.80% 6.26% 4.63% LENSAR -99.17%-737.30%-81.69% Which has stronger valuation & earnings, AVNS or LNSR? LENSAR has lower revenue, but higher earnings than Avanos Medical. LENSAR is trading at a lower price-to-earnings ratio than Avanos Medical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvanos Medical$687.80M0.83-$392.10M-$8.37-1.47LENSAR$53.49M2.95-$31.40M-$4.85-2.76 Do institutionals & insiders believe in AVNS or LNSR? 95.2% of Avanos Medical shares are owned by institutional investors. Comparatively, 40.2% of LENSAR shares are owned by institutional investors. 2.6% of Avanos Medical shares are owned by insiders. Comparatively, 38.5% of LENSAR shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more risk & volatility, AVNS or LNSR? Avanos Medical has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500. Comparatively, LENSAR has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500. Does the media prefer AVNS or LNSR? In the previous week, LENSAR had 1 more articles in the media than Avanos Medical. MarketBeat recorded 1 mentions for LENSAR and 0 mentions for Avanos Medical. Avanos Medical's average media sentiment score of 1.84 beat LENSAR's score of 0.62 indicating that Avanos Medical is being referred to more favorably in the media. Company Overall Sentiment Avanos Medical Very Positive LENSAR Positive SummaryAvanos Medical beats LENSAR on 8 of the 15 factors compared between the two stocks. Get LENSAR News Delivered to You Automatically Sign up to receive the latest news and ratings for LNSR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LNSR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LNSR vs. The Competition Export to ExcelMetricLENSARMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$157.87M$6.86B$5.49B$9.01BDividend YieldN/A1.16%5.39%4.10%P/E Ratio-2.7626.5526.7120.06Price / Sales2.95100.59419.59119.24Price / CashN/A21.0136.1356.90Price / Book31.884.738.065.59Net Income-$31.40M$173.18M$3.16B$248.50M7 Day Performance6.69%1.45%1.81%2.67%1 Month Performance-1.11%0.05%3.99%5.49%1 Year Performance193.64%28.11%35.40%21.00% LENSAR Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LNSRLENSAR1.3009 of 5 stars$13.39+2.3%$15.00+12.0%+203.7%$157.87M$53.49M-2.76110AVNSAvanos Medical2.4243 of 5 stars$12.25+0.3%N/A-36.6%$564.64M$689.20M-1.462,227EMBCEmbecta4.3639 of 5 stars$9.69+0.5%$19.33+99.5%-13.6%$563.39M$1.12B10.772,100BVSBioventus3.4127 of 5 stars$6.62-2.2%$14.33+116.5%+18.5%$543.79M$567.70M-10.851,200KIDSOrthoPediatrics4.2471 of 5 stars$21.48+0.5%$35.83+66.8%-23.9%$519M$204.73M-12.27200RXSTRxSight1.79 of 5 stars$13.00+2.6%$37.90+191.5%-77.0%$514.87M$139.93M-19.40220BFLYButterfly Network2.4162 of 5 stars$2.00+1.8%$4.00+100.5%+109.6%$484.69M$82.06M-6.88460News CoverageAnalyst ForecastAXGNAxoGen2.7116 of 5 stars$10.85+3.3%$24.50+125.8%+47.1%$478.21M$187.34M-72.33450Positive NewsHigh Trading VolumeDCTHDelcath Systems3.6298 of 5 stars$13.60+0.2%$24.00+76.5%+58.2%$472.59M$37.21M-27.2060Positive NewsSMLRSemler Scientific2.3291 of 5 stars$38.74+0.6%$71.00+83.3%+20.7%$429.34M$56.29M-14.84120Gap UpTMCITreace Medical Concepts2.6045 of 5 stars$5.88+2.3%$10.16+72.7%-8.1%$361.62M$209.36M-6.92250Positive News Related Companies and Tools Related Companies Avanos Medical Competitors Embecta Competitors Bioventus Competitors OrthoPediatrics Competitors RxSight Competitors Butterfly Network Competitors AxoGen Competitors Delcath Systems Competitors Semler Scientific Competitors Treace Medical Concepts Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LNSR) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredThe Pentagon just made a National Security move...This "awesome resource" could power America for 30,000 years... We sent one of our smartest researchers.......Stansberry Research | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredA grave, grave error.President Donald Trump made headlines last month with a staggering claim. He stated that since taking offic...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LENSAR, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LENSAR With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
